Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Inclusion Criteria: * Patients must have histologically or cytologically confirmed non-mucinous, epithelial stage 3 or 4 carcinoma of the ovary, fallopian tube or peritoneum. * Patients must not have received treatment for another malignancy within 3 years of enrollment (patients who have received hormone therapy within 3 years of enrollment are still eligible). * Patients must have received at least 3 but not more than 6 cycles of carboplatin-doublet based IV neoadjuvant chemotherapy and achieved at least stable disease (radiographically confirmed) at the conclusion of this therapy. * Age ≥ 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 * Patients must have adequate organ and marrow function as defined below (within 30 days of registration): * Absolute neutrophil count \>= 1,500/mcL (within 30 days of registration) * Platelets \>= 75,000/mcL (within 30 days of registration) * Total bilirubin =\< 1.5 mg/dL (within 30 days of registration) * Creatinine clearance \>= 50 mg/dL (within 30 days of registration) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) =\< 3 x institutional upper limit of normal (within 30 days of registration) * Alkaline phosphatase =\< 3 x institutional upper limit of normal (within 30 days of registration) * The effects of HIPEC on the developing human fetus are unknown. For this reason, and because carboplat…